secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001193125-22-145000
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics appoints Maggie FitzPatrick as Class II director with option grant and cash retainer
--------------------------------------------------------------------------------

- Appointed May 5, 2022; also joins nominating and corporate governance committee.
- Initial stock option grant with grant-date value of $209,093 vesting monthly over 3 years.
- Annual cash director retainer of $39,000 paid quarterly for board and committee service.
- FitzPatrick brings experience from Johnson & Johnson, Cigna, and Exelon; also serves on VistaGen board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/0001193125-22-145000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/d286325d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-145000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer